Image credit
We worked on a 25,000-words Simplified Chinese to English business proposal for the construction of a National gene detection technology application demonstration center in Algeria.
It consisted of a background study and statistical data of birth defects, genetic diseases leading to disabilities, and rising incidences of major illnesses in Algeria; contributing enormous strains to individual families and the society. It proposed that advances made in China and abroad in the biotechnology and genetics industry could help detect and treat illnesses by the 4P medical model – preventive medicine, predictive medicine, personalized medicine, and participatory medicine.
在每年超过3000例的新生聋儿中，由遗传因素所导致的耳聋约占60%。唐氏综合征发生率约为1/800-1/600，占小儿三体型染色体病的70%-80%，给社会带来了严重的经济负担，对家庭造成了巨大的心理压力和精神创伤。同时，伴随着经济、社会的快速发展，肿瘤、心血管疾病等重大疾病发病率也呈大幅攀升态势。
The proportion of newborn deafness in Algeria is around 1 % -3 %, and among more than 3,000 cases of newborn deafness each year, around 60% is caused by genetic factors. The incidence of Down syndrome is about 1/800-1/600, accounting for 70% -80% chance of occurrence in pediatric trichomes chromosome diseases, bringing serious economic strain to the community and causing enormous psychological pressure and mental stress on the family. At the same time, along with rapid economic and social development, incidences of cancer, cardiovascular disease, and other major diseases have shown a sharp upward trend.
近年来，国际上高度重视生物技术及基因产业的发展，注重发挥基因检测技术在遗传病的大规模筛查、肿瘤等重大疾病的个体化诊断等方面的应用，发布了一系列政策支持产业发展和防治应用。
Recent years has seen the international community highly valuing the progress made in the biotechnology and genetics industry, with special attention focused on expanding genetics testing technology to play a large-scale role in the screening of genetic diseases, cancer, and other major diseases, in individualized diagnosis and in other applications. A series of policies to support the industry in application development, prevention and treatment have been issued.
基因检测产业逐步进入快速发展的成长期。基因检测是目前基因产业中能够应用且应用范围较广的一项能够造福人类健康的事业。自人类基因组计划（HGP）实施完成以来，人们对于基因的认识逐步加深，基因检测技术迅猛发展，基因检测产业链逐步完整。越来越多的基因检测技术从科研走向临床并得以证实，主要体现在预测疾病风险、辅助疾病诊断、指导健康管理及服务个体化医疗等方面。
The genetic testing industry has gradually moved into a rapid development growth cycle. Within the genetics industry right now, genetic testing can be readily utilized with a broad range of applications, evolving into a business that can benefit human health. Since the complete implementation of the Human Genome Project (HGP) people’s understanding of genes has gradually deepened, genetic detection technology has rapidly developed, with the genetic testing industry chain gradually coming together. There are more and more genetic testing techniques moving from clinical research to clinically confirmed, mainly reflected in areas of disease risk prediction, assisting in the diagnosis of diseases, and providing guidance in health management and personalized care services.
1978年，著名美籍华裔科学家简悦威等应用液相DNA分子杂交成功地进行了镰形细胞贫血症的基因诊断，标志着基因检测的诞生，产生了疾病诊断学领域的革命性影响。1998年，美国正式启动基因芯片计划，使得基因筛查更加快速、简便。2000年6月22日，人类基因组计划草图绘制完毕。2005年底，454公司推出第一个基于焦磷酸测序原理的高通量基因组测序系统。2013年9月，illumina公司的MiseqDx平台首次通过了美国FDA的技术认证，作为开放平台和囊纤维化的试剂产品准许进入临床，标志着经过10年的发展，高通量测序技术已从纯科学研究的平台进入临床诊断领域。
In 1978, the famous Chinese American scientist Jane Yue Wei and colleagues used liquid-phase DNA molecular hybridization to successfully carry out genetic diagnosis on sickle cell anemia, marking the birth of genetic testing, resulting in a revolution in the field of disease diagnosis. In 1998, the United States officially launched the gene chip program, enabling quicker and easier gene screening. On June 22, 2000, the human genome plan sketch was completed. At the end of 2005, 454 Company launched the first high-throughput genome sequencing system based on the principle of pyrosequencing. In September 2013, Illumina’s MiseqDx platform passed the U.S. FDA’s technical certification for the first time as an open platform allowing capsule fibrosis reagent products to enter clinical use, marking the day that after 10 years of development, high-throughput sequencing technology has evolved from a pure science research platform into the field of clinical diagnosis.
随着基因检测技术的发展，在欧美发达国家，基因市场已初具规模，不仅有众多的专业公司提供基因检测服务，还有少量的基因修复药物及基因食品的研发、生产、销售。
With the development of gene detection technology in developed countries like Europe and America, the gene market has begun to take shape. Not only do a large number of professional companies provide genetic testing services, there are a few that develop gene repair drugs, research and develop, produce and sell genetic food.
随着基因技术和健康理念的发展，现代医学进入“4P”医学模式（4pmedicalmodel）：1.预防医学(Preventive Medicine)；2.预测医学(Predictive Medicine)；3.个体医学(Personalized Medicine)；4.参与医学(Participatory Medicine)。“4P”医学模式以解决慢性病问题为首要目标。
With the development of genetic technology and healthcare concepts, modern medicine enters a “4P” medical model (4pmedicalmodel): 1. Preventive Medicine; 2. Predictive Medicine; 3. Personalized Medicine; 4. Participatory Medicine. The “4P” Medical model aims to solve the problem of chronic diseases as its primary objective.
预防医学包括多层次的行动：首先是人类通过自身健康习惯主动对某些疾病的预防；第二层含义在于政府的政策干预，通过政策推动人们提高对疾病及其预防的积极性，普及预防医学常识，能够提高整个社会对疾病的预防水平；第三层则是人类通过对所处环境的改变，例如在绿色生态城市中选择低碳的生活方式等。
Preventive medicine involves multi-tiered actions: Foremost is people taking the initiative to prevent certain diseases through their own health habits; second tier is government policy intervention to encourage people taking proactive actions towards disease prevention through public policies, and making preventive medicine knowledge universal in order to improve the level of disease prevention across the community; the third tier is people choosing a green eco-city, embracing a low-carbon lifestyle through changing their environment.
预测医学，医疗产业掘金“治未病”已成“大健康管理”必然趋势。2013年，美国影星安吉丽娜·朱莉实施了双侧乳腺切除手术：因为基因测序的结果显示，她与她的母亲及姨妈一样，携带有BRCA1、BRCA2基因，具有较高的罹患卵巢癌和乳腺癌的风险。为规避这一风险，安吉丽娜提前进行了预测性治疗，将患乳腺癌的风险从87%降到5%。在未来，这种基于基因测序的预测性治疗或成趋势。2011年，美国一项1463名受访者参与的的调查发现，很多人愿意做疾病的预测性检验，1463名受访者中，76%的人愿意接受老年痴呆症，乳腺癌，前列腺癌或者关节炎的假设检验。受访者的答案随疾病种类，费用和预测准确性而改变。意愿最高的测试是前列腺癌（87%），其次是乳腺癌（81%），再次是老年痴呆症（72%）。
The emergence of preventive medicine in the medical industry has seen “disease-cure” become an inevitable “macro health management” trend. In 2013, U.S. movie star Angelina Jolie had double mastectomy surgery performed to reduce her cancer risks after learning the results of her gene sequencing. Similar to her mother and aunt, she carried the BRCA1, BRCA2 gene, signifying she had a higher risk of developing ovarian cancer and breast cancer. To avoid this risk, Angelina had proactively made a preventive treatment, reducing her risk of developing breast cancer from 87% to 5%. This kind of preventive medicine based on genetic sequencing may very likely become a trend. In 2011, a survey of 1,463 respondents in the United States found that many people were willing to undergo predictive testing of diseases, with 76% of these 1,463 respondents willing to test for Alzheimer’s disease, breast cancer, prostate cancer, or arthritis. Respondents’ answers vary with the type, cost, and predictive accuracy of different diseases. The highest willingness was for prostate cancer (87%), followed by breast cancer (81%), and Alzheimer’s (72%).
个体化诊疗，基因检测、诊断及治疗已经进入个性化医疗时代，以技术为核心、疾病为基础的检测、诊断平台是基因检测技术应用的主要方向。2004年诺贝尔化学奖得主阿龙·切哈诺沃认为，今后必将进入“个性化医疗”新时代。未来的治疗方案将根据患者的信息量身定制。近年来，以基因测序、癌症早期筛查及再生医学等为代表的个性化医疗正方兴未艾：在临床上，基因检测技术通过检测基因诊断疾病，明确病因，找出药物相关基因标记，提高治疗效果，降低医疗成本；日本一名70岁的渗出型老年黄斑变性女患者接受了iPS细胞移植手术，该手术为世界首例，标志着使用iPS细胞的再生医学迈出了重要的一步。
Individualized diagnosis and treatment, gene detection, diagnosis, and treatment have entered the era of personalized medicine, using technology as the core disease diagnostic platform is the main direction of gene detection technology applications. The 2004 Nobel Prize winner Aaron Chernovo said that from now on we will enter a new “personalized medical” era. Future treatment options will be tailored to patient’s information. In recent years, individualized medicine, represented by gene sequencing, early screening of cancer and regenerative medicine, is ascending: In clinical practice, gene detection technology improves therapeutic results by detecting disease gene in diagnosis, clarifying the root cause, identifying drug-related gene markers, reducing medical costs; a 70-year-old Japanese female patient with exudative age-related macular degeneration underwent iPS cell transplantation, the surgery was the world’s first, marking it an important step forward using iPS cell in regenerative medicine.
全民参与，在现代社会，随着民众自我意识和健康理念的提高，越来越多的患者从被动由医生来决定如何进行治疗的角色中跳出来，主动地参与到对自身健康的维护中。这种参与性不止是鼓励患者在疾病诊疗过程中增加与医生的互动性、提高用药依从性等，更多的是旨在提高全人群的健康管理理念。人们将逐渐意识到，诸如女性体温监测、血压血糖监控等这些细而微的健康管理将如何改善自己的健康状况和就医体验。如何治病更多的是依靠医生，但生不生病，许多时候是由自己的行为决定。
With the improvement of people’s self-awareness and health concept in the modern society, more and more patients have evolved from passively allowing doctors decide their treatment methods, to taking a more proactive role to initiate and participate in the maintenance of their own health. Not only do these types of participation encourage patients to have more interaction with their doctors during the course of disease diagnosis and treatment, it also improves patients’ drug compliance, with the objective to improve people’s health management concept on the whole. People will gradually realize that fine, micro health management, such as temperature and blood glucose monitoring for women, etc., will improve their overall health condition and doctor’s visit experience. The way to a cure depends on the doctor, but not getting sick, a lot of times, depends on one’s own behavior and decisions.
We further worked on the technology and application for detections of the following diseases, the construction model of the center, and investment details. The content was meticulously researched to ensure its accuracy. Our client was happy with our efforts.
肿瘤分子检测、心脑血管病分子检测、感染性疾病分子检测等多个实验室，主要提供如下检测服务：遗传性耳聋基因检测、唐氏综合征基因检测、新生儿遗传代谢病串联质谱筛查、染色体核型分析及FISH检测、染色体异常检测、地中海贫血检测、其他单基因病检测、遗传性肿瘤基因检测、肿瘤相关病毒基因检测、血浆miRNA标志物检测、乳腺癌预后基因检测、白血病融合基因检测、多发性骨髓瘤基因检测、肿瘤个体化用药基因检测、心脑血管病个体化用药基因检测、人乳头瘤病毒（HPV）分型检测、肝炎分子诊断、分枝杆菌检测、其他感染性疾病检测。
Molecular genetic disease detection, cancer molecular detection, cardiovascular and cerebrovascular diseases molecular detection, molecular detection of infectious and other diseases. Mainly providing genetic deafness gene detection, Down syndrome gene detection, neonatal genetic metabolic disease tandem mass spectrometry screening, chromosome karyotype analysis and FISH detection, chromosomal abnormalities detection, thalassemia detection, other single gene disease detection, hereditary cancer gene detection, tumor-related virus gene detection, plasma miRNA marker detection, breast cancer prognosis gene detection, leukemia fusion gene detection, multiple myeloma gene detection, individualized cancer drug detection, individualized cardiovascular and cerebrovascular disease drug detection, human papillomavirus (HPV) typing, hepatitis molecular diagnostics, detection of mycobacteria, other infectious diseases.
Large, technical translation. Nice work Bonnie – Ken, Los Angeles
